CME Group (NASDAQ:CME) PT Raised to $258.00

CME Group (NASDAQ:CME) had its target price lifted by analysts at Oppenheimer from $245.00 to $258.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the financial services provider’s stock. Oppenheimer’s price target would suggest a potential upside of 14.09% from the stock’s current price.

Several other research firms have also recently weighed in on CME. Piper Sandler upped their price objective on shares of CME Group from $225.00 to $240.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 8th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $235.00 price target on shares of CME Group in a report on Thursday. JPMorgan Chase & Co. increased their price target on shares of CME Group from $187.00 to $191.00 and gave the stock an “underweight” rating in a research report on Thursday, July 25th. Citigroup boosted their price objective on shares of CME Group from $250.00 to $255.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Barclays upped their target price on CME Group from $219.00 to $231.00 and gave the stock an “equal weight” rating in a research note on Thursday. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, CME Group has an average rating of “Hold” and a consensus price target of $222.07.

CME Group Stock Performance

Shares of NASDAQ:CME opened at $226.14 on Thursday. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.10. CME Group has a 12-month low of $190.70 and a 12-month high of $230.36. The company’s 50 day moving average price is $218.57 and its two-hundred day moving average price is $208.81. The firm has a market cap of $81.43 billion, a PE ratio of 25.70, a PEG ratio of 7.76 and a beta of 0.55.

CME Group (NASDAQ:CME) last posted its quarterly earnings data on Wednesday, October 23rd. The financial services provider reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.03. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.59 billion. CME Group had a return on equity of 12.82% and a net margin of 56.98%. The company’s revenue was up 18.4% on a year-over-year basis. During the same quarter last year, the company earned $2.25 EPS. Equities research analysts predict that CME Group will post 10.04 earnings per share for the current year.

Insider Transactions at CME Group

In other CME Group news, CFO Lynne Fitzpatrick sold 754 shares of the company’s stock in a transaction that occurred on Sunday, September 15th. The shares were sold at an average price of $216.99, for a total value of $163,610.46. Following the completion of the transaction, the chief financial officer now directly owns 13,261 shares in the company, valued at approximately $2,877,504.39. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other CME Group news, CFO Lynne Fitzpatrick sold 754 shares of the company’s stock in a transaction dated Sunday, September 15th. The stock was sold at an average price of $216.99, for a total value of $163,610.46. Following the sale, the chief financial officer now owns 13,261 shares in the company, valued at approximately $2,877,504.39. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bryan T. Durkin sold 7,593 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $214.59, for a total value of $1,629,381.87. Following the transaction, the director now owns 55,607 shares of the company’s stock, valued at $11,932,706.13. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On CME Group

A number of institutional investors have recently modified their holdings of the company. Oak Harvest Investment Services grew its stake in CME Group by 66.5% during the first quarter. Oak Harvest Investment Services now owns 45,093 shares of the financial services provider’s stock worth $9,708,000 after purchasing an additional 18,017 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of CME Group by 21.2% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 48,205 shares of the financial services provider’s stock worth $9,477,000 after buying an additional 8,443 shares during the period. Duality Advisers LP bought a new stake in shares of CME Group in the 1st quarter valued at $1,455,000. SG Americas Securities LLC lifted its position in shares of CME Group by 312.2% during the 1st quarter. SG Americas Securities LLC now owns 56,768 shares of the financial services provider’s stock valued at $12,222,000 after acquiring an additional 42,996 shares during the period. Finally, Cetera Investment Advisers lifted its position in shares of CME Group by 429.1% during the 1st quarter. Cetera Investment Advisers now owns 47,521 shares of the financial services provider’s stock valued at $10,231,000 after acquiring an additional 38,540 shares during the period. 87.75% of the stock is owned by institutional investors.

CME Group Company Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.